新型冠狀病毒肺炎嚴重程度相關生物學預測因子的研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

黃秋芬 ^1,2 ,  曾惠清 ^1,2 , 王洺輝 ^1,2 , 余慧蓮 ² , 蔡芋晴 ^1,2 , 李琪 ² , 李艷萍 ^1,2

1. ;
2. ;

Corresponding?author：

曾惠清, Email: 13606080893@139.com

Keywords：

DOI：

10.7507/1671-6205.202101010

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 黃秋芬, 曾惠清, 王洺輝, 余慧蓮, 蔡芋晴, 李琪, 李艷萍. 新型冠狀病毒肺炎嚴重程度相關生物學預測因子的研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2022, 21(1): 71-75. doi: 10.7507/1671-6205.202101010 Copy

1.	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395: 497-506.
2.	Li QB, Cao YL, Chen L, et al. Hematological features of persons with COVID-19. Leukemia, 2020, 34(8): 2163-2172.
3.	ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA, 2012, 307(23): 2526-2533.
4.	Yang XB, Yu Y, Xu JQ, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med, 2020, 8(5): 475-481.
5.	Li XC, Xu SY, Yu MQ, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol, 2020, 146(1): 110-118.
6.	Yarmohammadi A, Yarmohammadi M, Fakhri S, et al. Targeting pivotal inflammatory pathways in COVID-19: a mechanistic review. Eur J Pharmacol, 2021, 890: 173620.
7.	Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest, 2020, 130(5): 2620-2629.
8.	Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med, 2020, 26(10): 1636-1643.
9.	Galván-Román JM, Rodríguez-García SC, Roy-Vallejo E, et al. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study. J Allergy Clin Immunol, 2021, 147(1): 72-80.
10.	Vultaggio A, Vivarelli E, Virgili G, et al. Prompt predicting of early clinical deterioration of moderate-to-severe COVID-19 patients: usefulness of a combined score using IL-6 in a preliminary study. J Allergy Clin Immunol Pract, 2020, 8(8): 2575-2581.
11.	Chen W, Zheng K, Liu S, et al. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob, 2020, 19(1): 18.
12.	Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ, 2020: 369.
13.	Tan CC, Huang Y, Shi FX, et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virol, 2020, 92(7): 856-862.
14.	Luo XM, Zhou W, Yan XJ, et al. Prognostic value of c-reactive protein in patients with coronavirus 2019. Clin Infect Dis, 2020, 71(16): 2174-2179.
15.	Sproston N, Ashworth J. Role of C-reactive protein at sites of inflammation and infection. Front Immunol, 2018, 9: 754.
16.	Henry B, De Oliveira M, Benoit S, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med, 2020, 58(7): 1021-1028.
17.	Xu B, Fan CY, Wang AL, et al. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China. J Infect, 2020, 81(1): e51-e60.
18.	Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect, 2020, 81(1): e6-e12.
19.	Ma A, Cheng JL, Yang J, et al. Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients. Crit Care, 2020, 24(1): 288.
20.	Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell, 2020, 181(5): 1036-1045.e9.
21.	Hadjadj J, Yatim N, Barnabei L, et al. Impaired type Ⅰ interferon activity and inflammatory responses in severe COVID-19 patients. Science, 2020, 369(6504): 718-724.
22.	Smadja DM, Guerin CL, Chocron R, et al. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Angiogenesis, 2020, 23(4): 611-620.
23.	Kornilov S, Lucas I, Jade K, et al. Plasma levels of soluble ACE2 are associated with sex, metabolic syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in COVID-19. Crit Care, 2020, 24(1): 452.
24.	Liao DY, Zhou F, Luo LL, et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol, 2020, 7(9): e671-e678.
25.	Goyal P, Choi J, Pinheiro L, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med, 2020, 382(24): 2372-2374.
26.	Bi X, Su Z, Yan H, et al. Prediction of severe illness due to COVID-19 based on an analysis of initial fibrinogen to albumin ratio and platelet count. Platelets, 2020, 31(5): 674-679.
27.	Jiang S, Huang Q, Xie W, et al. The association between severe COVID-19 and low platelet count: evidence from 31 observational studies involving 7613 participants. Br J Haematol, 2020, 190(1): e29-e33.
28.	Han Y, Zhang HD, Mu SC, et al. Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study. Aging (Albany NY), 2020, 12(12): 11245-11258.
29.	Chen X, Huang M, Xiao Z, et al. Lactate dehydrogenase elevations is associated with severity of COVID-19: a meta-analysis. Crit Care, 2020, 24(1): 459.
30.	Li C, Ye JF, Chen QJ, et al. Elevated lactate dehydrogenase (LDH) level as an independent risk factor for the severity and mortality of COVID-19. Aging (Albany NY), 2020, 12(15): 15670-15681.
31.	Udomsinprasert W, Jittikoon J, Sangroongruangsri S, et al. Circulating levels of interleukin-6 and interleukin-10, but not tumor necrosis factor-alpha, as potential biomarkers of severity and mortality for COVID-19: systematic review with meta-analysis. J Clin Immunol, 2021, 41(1): 11-22.
32.	Lindsley A, Schwartz J, Rothenberg M. Eosinophil responses during COVID-19 infections and coronavirus vaccination. J Allergy Clin Immunol, 2020, 146(1): 1-7.
33.	Huang JJ, Zhang ZC, Liu SF, et al. Absolute eosinophil count predicts intensive care unit transfer among elderly COVID-19 patients from general isolation wards. Front Med (Lausanne), 2020, 7: 585222.
34.	Du YZ, Tu L, Zhu PJ, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. Am J Respir Crit Care Med, 2020, 201(11): 1372-1379.
35.	程玉生, 周云, 朱孟德, 等. 嗜酸性粒細胞減少在新型冠狀病毒肺炎患者中的臨床意義. 中國呼吸與危重監護雜志, 2021, 20(5): 315-319.
36.	Ruscitti P, Berardicurti O, Barile A, et al. Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander?. Ann Rheum Dis, 2020, 79(11): 1515-1516.
37.	Taneri PE, Gómez-Ochoa SA, Llanaj E, et la. Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Eur J Epidemiol, 2020, 35(8): 763-773.
38.	Lin Z, Long F, Yang Y, et al. Serum ferritin as an independent risk factor for severity in COVID-19 patients. J Infect, 2020, 81(4): 647-679.
39.	Zhou F, Yu T, Du RH, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020, 395(10229): 1054-1062.
40.	Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity, 2005, 23(5): 479-490.
41.	Jackson D, Makrinioti H, Rana B, et al. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med, 2014, 190(12): 1373-82.
42.	Le Goffic R, Arshad M, Rauch M, et al. Infection with influenza virus induces IL-33 in murine lungs. Am J Respir Cell Mol Biol, 2011, 45(6): 1125-1132.
43.	Burke H, Freeman A, Cellura DC, et al. Inflammatory phenotyping predicts clinical outcome in COVID-19. Respir Res, 2020, 21(1): 245.
44.	Zeng ZK, Hong XY, Li YH, et al. Serum-soluble ST2 as a novel biomarker reflecting inflammatory status and illness severity in patients with COVID-19. Biomark Med, 2020, 14(17): 1619-1629.
45.	Han H, Ma QF, Li C, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect, 2020, 9(1): 1123-1130.
46.	Zhao Y, Qin L, Zhang P, et al. Longitudinal COVID-19 profiling associates IL-1 RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight, 2020, 5(13): e139834.
47.	Lu LG, Zhang H, Dauphars DJ, et al. A potential role of interleukin 10 in COVID-19 pathogenesis. Trends Immunol, 2021, 42(1): 3-5.
48.	Shen B, Yi X, Sun YT, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell, 2020, 182(1): 59-72.
49.	Yang Y, Shen CG, Li JX, et al. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol, 2020, 146(1): 119-127.
50.	McElvaney OJ, McEvoy NL, McElvaney OF, et al. Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med, 2020, 202(6): 812-821.
51.	Sugiyama M, Kinoshita N, Ide S, et al. Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19. Gene, 2021, 766: 145145.
52.	Bertin D, Brodovitch A, Beziane A, et al. Anticardiolipin IgG autoantibody level is an independent risk factor for COVID-19 severity. Arthritis Rheumatol, 2020, 72(11): 1953-1955.

1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395: 497-506.
2. Li QB, Cao YL, Chen L, et al. Hematological features of persons with COVID-19. Leukemia, 2020, 34(8): 2163-2172.
3. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA, 2012, 307(23): 2526-2533.
4. Yang XB, Yu Y, Xu JQ, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med, 2020, 8(5): 475-481.
5. Li XC, Xu SY, Yu MQ, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol, 2020, 146(1): 110-118.
6. Yarmohammadi A, Yarmohammadi M, Fakhri S, et al. Targeting pivotal inflammatory pathways in COVID-19: a mechanistic review. Eur J Pharmacol, 2021, 890: 173620.
7. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest, 2020, 130(5): 2620-2629.
8. Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med, 2020, 26(10): 1636-1643.
9. Galván-Román JM, Rodríguez-García SC, Roy-Vallejo E, et al. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study. J Allergy Clin Immunol, 2021, 147(1): 72-80.
10. Vultaggio A, Vivarelli E, Virgili G, et al. Prompt predicting of early clinical deterioration of moderate-to-severe COVID-19 patients: usefulness of a combined score using IL-6 in a preliminary study. J Allergy Clin Immunol Pract, 2020, 8(8): 2575-2581.
11. Chen W, Zheng K, Liu S, et al. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob, 2020, 19(1): 18.
12. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ, 2020: 369.
13. Tan CC, Huang Y, Shi FX, et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virol, 2020, 92(7): 856-862.
14. Luo XM, Zhou W, Yan XJ, et al. Prognostic value of c-reactive protein in patients with coronavirus 2019. Clin Infect Dis, 2020, 71(16): 2174-2179.
15. Sproston N, Ashworth J. Role of C-reactive protein at sites of inflammation and infection. Front Immunol, 2018, 9: 754.
16. Henry B, De Oliveira M, Benoit S, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med, 2020, 58(7): 1021-1028.
17. Xu B, Fan CY, Wang AL, et al. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China. J Infect, 2020, 81(1): e51-e60.
18. Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect, 2020, 81(1): e6-e12.
19. Ma A, Cheng JL, Yang J, et al. Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients. Crit Care, 2020, 24(1): 288.
20. Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell, 2020, 181(5): 1036-1045.e9.
21. Hadjadj J, Yatim N, Barnabei L, et al. Impaired type Ⅰ interferon activity and inflammatory responses in severe COVID-19 patients. Science, 2020, 369(6504): 718-724.
22. Smadja DM, Guerin CL, Chocron R, et al. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Angiogenesis, 2020, 23(4): 611-620.
23. Kornilov S, Lucas I, Jade K, et al. Plasma levels of soluble ACE2 are associated with sex, metabolic syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in COVID-19. Crit Care, 2020, 24(1): 452.
24. Liao DY, Zhou F, Luo LL, et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol, 2020, 7(9): e671-e678.
25. Goyal P, Choi J, Pinheiro L, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med, 2020, 382(24): 2372-2374.
26. Bi X, Su Z, Yan H, et al. Prediction of severe illness due to COVID-19 based on an analysis of initial fibrinogen to albumin ratio and platelet count. Platelets, 2020, 31(5): 674-679.
27. Jiang S, Huang Q, Xie W, et al. The association between severe COVID-19 and low platelet count: evidence from 31 observational studies involving 7613 participants. Br J Haematol, 2020, 190(1): e29-e33.
28. Han Y, Zhang HD, Mu SC, et al. Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study. Aging (Albany NY), 2020, 12(12): 11245-11258.
29. Chen X, Huang M, Xiao Z, et al. Lactate dehydrogenase elevations is associated with severity of COVID-19: a meta-analysis. Crit Care, 2020, 24(1): 459.
30. Li C, Ye JF, Chen QJ, et al. Elevated lactate dehydrogenase (LDH) level as an independent risk factor for the severity and mortality of COVID-19. Aging (Albany NY), 2020, 12(15): 15670-15681.
31. Udomsinprasert W, Jittikoon J, Sangroongruangsri S, et al. Circulating levels of interleukin-6 and interleukin-10, but not tumor necrosis factor-alpha, as potential biomarkers of severity and mortality for COVID-19: systematic review with meta-analysis. J Clin Immunol, 2021, 41(1): 11-22.
32. Lindsley A, Schwartz J, Rothenberg M. Eosinophil responses during COVID-19 infections and coronavirus vaccination. J Allergy Clin Immunol, 2020, 146(1): 1-7.
33. Huang JJ, Zhang ZC, Liu SF, et al. Absolute eosinophil count predicts intensive care unit transfer among elderly COVID-19 patients from general isolation wards. Front Med (Lausanne), 2020, 7: 585222.
34. Du YZ, Tu L, Zhu PJ, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. Am J Respir Crit Care Med, 2020, 201(11): 1372-1379.
35. 程玉生, 周云, 朱孟德, 等. 嗜酸性粒細胞減少在新型冠狀病毒肺炎患者中的臨床意義. 中國呼吸與危重監護雜志, 2021, 20(5): 315-319.
36. Ruscitti P, Berardicurti O, Barile A, et al. Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander?. Ann Rheum Dis, 2020, 79(11): 1515-1516.
37. Taneri PE, Gómez-Ochoa SA, Llanaj E, et la. Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Eur J Epidemiol, 2020, 35(8): 763-773.
38. Lin Z, Long F, Yang Y, et al. Serum ferritin as an independent risk factor for severity in COVID-19 patients. J Infect, 2020, 81(4): 647-679.
39. Zhou F, Yu T, Du RH, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020, 395(10229): 1054-1062.
40. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity, 2005, 23(5): 479-490.
41. Jackson D, Makrinioti H, Rana B, et al. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med, 2014, 190(12): 1373-82.
42. Le Goffic R, Arshad M, Rauch M, et al. Infection with influenza virus induces IL-33 in murine lungs. Am J Respir Cell Mol Biol, 2011, 45(6): 1125-1132.
43. Burke H, Freeman A, Cellura DC, et al. Inflammatory phenotyping predicts clinical outcome in COVID-19. Respir Res, 2020, 21(1): 245.
44. Zeng ZK, Hong XY, Li YH, et al. Serum-soluble ST2 as a novel biomarker reflecting inflammatory status and illness severity in patients with COVID-19. Biomark Med, 2020, 14(17): 1619-1629.
45. Han H, Ma QF, Li C, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect, 2020, 9(1): 1123-1130.
46. Zhao Y, Qin L, Zhang P, et al. Longitudinal COVID-19 profiling associates IL-1 RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight, 2020, 5(13): e139834.
47. Lu LG, Zhang H, Dauphars DJ, et al. A potential role of interleukin 10 in COVID-19 pathogenesis. Trends Immunol, 2021, 42(1): 3-5.
48. Shen B, Yi X, Sun YT, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell, 2020, 182(1): 59-72.
49. Yang Y, Shen CG, Li JX, et al. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol, 2020, 146(1): 119-127.
50. McElvaney OJ, McEvoy NL, McElvaney OF, et al. Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med, 2020, 202(6): 812-821.
51. Sugiyama M, Kinoshita N, Ide S, et al. Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19. Gene, 2021, 766: 145145.
52. Bertin D, Brodovitch A, Beziane A, et al. Anticardiolipin IgG autoantibody level is an independent risk factor for COVID-19 severity. Arthritis Rheumatol, 2020, 72(11): 1953-1955.

Previous Article
Clinical characteristics of 5 cases of Chlamydia psittaci pneumonia diagnosed by metagenomics next-generation sequencing

Chinese Journal of Respiratory and Critical Care Medicine

新型冠狀病毒肺炎嚴重程度相關生物學預測因子的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content